David B Clifford, Florin Vaida, Yu-Ting Kao, Donald R Franklin, Scott L Letendre, Ann C Collier, Christina M Marra, Benjamin B Gelman, Justin C McArthur, Susan Morgello, David M Simpson, Igor Grant, Robert K Heaton
OBJECTIVE: To investigate the effect of hepatitis C virus (HCV) on neurocognitive performance in chronically HIV-infected patients enrolled in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. METHODS: A total of 1,582 participants in CHARTER who were tested for HCV antibody underwent neurocognitive testing; serum HCV RNA was available for 346 seropositive patients. Neurocognitive performance was compared in 408 HCV-seropositive and 1,174 HCV-seronegative participants and in a subset of 160 seropositive and 707 seronegative participants without serious comorbid neurologic conditions that might impair neurocognitive performance, using linear regression and taking into account HIV-associated and demographic factors (including IV drug use) and liver function...
January 20, 2015: Neurology